Ocugen Patient Engagement

Home
United States
Malvern, PA
Ocugen Patient Engagement

A fully integrated, patient-centric biotech company focused on vaccines and gene therapies.

09/28/2026

A new pathway for OCU400 is creating an opportunity to expand global access for people living with retinitis pigmentosa.

Through the Bahamas Longevity and Regenerative Therapies Board, Ocugen is advancing patient access to OCU400 under a regulated Expanded Access Program with commercial pricing.

Hear from Shankar Musunuri, PhD, MBA, Chairman, CEO and Co-Founder of Ocugen, on what this means for OCU400, patients, and the potential to bring innovative gene therapies to people around the world.

To learn more: https://lnkd.in/ed3ibE9q

The Ministry of Health & Wellness Bahamas

09/25/2026

OCU400, our novel modifier gene therapy for retinitis pigmentosa, has been granted provisional approval and priority designation from the Bahamas Longevity and Regenerative Therapies Board, within The Ministry of Health & Wellness Bahamas.

“Our partnership marks an important milestone for Ocugen, creating a unique opportunity to provide global access through the Bahamas to OCU400 for people suffering from retinitis pigmentosa,” shared Shankar Musunuri, PhD, MBA, Chairman, CEO and Co-Founder of Ocugen.

We are committed to addressing unmet medical need and expanding global patient access to our novel treatment through commercial pricing evidenced with cost-effectiveness for a one-time broad treatment of RP.

OCU400 continues to advance through Phase 3, with topline data expected in the first quarter of 2027 and a Biologics License Application (BLA) submission planned for the second quarter of 2027.

Read the full announcement: https://bit.ly/4xNFDZR

09/22/2026

What is OCU410, and what does Phase 3 clinical trial mean?

OCU410 is an investigational gene therapy with the potential to treat geographic atrophy secondary to dry age-related macular degeneration.

Swipe through for a simple look at OCU410 and why Phase 3 is an important step in clinical development.

09/08/2026

Central vision plays an important role in everyday activities, from reading and recognizing faces to navigating the world around us.

Geographic atrophy (GA) can affect the macula, the part of the retina responsible for sharp, central vision. Understanding how GA can impact vision is an important step in raising awareness.

To learn more about GA, speak with an ophthalmologist and help raise awareness by sharing this information.

09/04/2026

We were pleased to welcome Pennsylvania State Rep. Lisa Borowski and Rep. Paul Friel to Ocugen for a visit with Chairman, CEO and Co-Founder Shankar Musunuri, PhD, MBA, and members from our leadership team this week.

The visit provided an opportunity to share our pipeline, exchange perspectives on the future of biotech, and discuss how Pennsylvania can continue supporting companies working to bring innovative therapies to patients globally.

As co-sponsors of bipartisan HB 2162, we thank Representatives Borowski and Friel for their leadership and commitment to streamlining Pennsylvania’s licensing process for pharmaceutical and biomedical companies, helping to create an environment where innovation, jobs, and life sciences can grow.

We’re grateful for their time, thoughtful conversation, and continued commitment to Pennsylvania’s biotech community.

To learn more about HB 2162, visit https://bit.ly/HB2162.

09/01/2026

An important step forward for OCU410 and the millions of people worldwide living with geographic atrophy.

Today, Chairman, CEO, and Co-Founder Shankar Musunuri, PhD, MBA, announced that the first patient has been dosed in our global Phase 3 clinical trial of OCU410. This milestone brings us closer to the potential of a one-time treatment for life and our target of three BLAs by 2028.

Learn more: bit.ly/4qNMBMk

08/19/2026

Healthy vision starts with a healthy retina. Learn how geographic atrophy affects the retina and why early awareness matters.

Follow Ocugen for more educational content on retinal diseases and vision research.

08/11/2026

Your vision can change gradually, often without noticeable symptoms. That's why early and regular eye exams are one of the best ways to detect potential vision problems and protect your long-term eye health. Taking action today can help preserve your sight for tomorrow.

Whether you're due for an eye exam or already have one on the calendar, make routine eye care a priority and encourage your loved ones to do the same.

07/27/2026

For years, Manny adapted to the everyday challenges of retinitis pigmentosa, from losing his night vision to relying on loved ones to navigate the world around him. But he never stopped believing in the power of research.

As the third participant to receive OCU400 in a clinical trial, Manny shares how taking a chance on research gave him renewed hope and why he continues to encourage others to consider participating in clinical trials.

Read Manny's story from the Foundation Fighting Blindness: https://bit.ly/3TWCV5S

07/21/2026

Stargardt disease affects the retina, the light-sensitive tissue at the back of the eye that plays a critical role in vision.

Ocugen is advancing OCU410ST, an investigational modifier gene therapy designed as a potential one-time treatment approach for Stargardt disease. By targeting multiple biological pathways associated with the disease, OCU410ST is being evaluated for its potential to preserve retinal structure and visual function.

Learn more about our commitment to patients and their stories: https://bit.ly/4p0fqVc. If you have questions about Stargardt disease, speak with your healthcare provider.

Address

11 Great Valley Parkway
Malvern, PA
19355

Website

https://ocugen.com/

Alerts

Be the first to know and let us send you an email when Ocugen Patient Engagement posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Ocugen Patient Engagement:

Want your business to be the top-listed engineering company in Malvern?